Insider Selling: Timothy P. Coughlin Sells 1,750 Shares of Neurocrine Biosciences Stock (NBIX)
Neurocrine Biosciences (NASDAQ:NBIX) CFO Timothy P. Coughlin unloaded 1,750 shares of Neurocrine Biosciences stock on the open market in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $18.56, for a total value of $32,480.00. Following the completion of the sale, the chief financial officer now directly owns 97,874 shares in the company, valued at approximately $1,816,541. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
A number of research firms have recently commented on NBIX. Analysts at Nomura initiated coverage on shares of Neurocrine Biosciences in a research note to investors on Wednesday, January 8th. They set a “buy” rating on the stock. Separately, analysts at Morgan Stanley downgraded shares of Neurocrine Biosciences from an “overweight” rating to an “equal weight” rating in a research note to investors on Wednesday, January 8th. They now have a $16.00 price target on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Neurocrine Biosciences from $16.00 to $23.00 in a research note to investors on Wednesday, January 8th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Neurocrine Biosciences has an average rating of “Buy” and a consensus target price of $18.73.
Neurocrine Biosciences (NASDAQ:NBIX) traded down 2.61% during mid-day trading on Monday, hitting $18.65. The stock had a trading volume of 1,568,737 shares. Neurocrine Biosciences has a 1-year low of $8.57 and a 1-year high of $19.34. The stock’s 50-day moving average is $10.89 and its 200-day moving average is $11.96. The company’s market cap is $1.256 billion.
Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings data on Tuesday, October 29th. The company reported ($0.17) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.20) by $0.03. The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.79 million. During the same quarter in the prior year, the company posted ($0.05) earnings per share. The company’s quarterly revenue was down 92.2% on a year-over-year basis. Analysts expect that Neurocrine Biosciences will post $-0.70 EPS for the current fiscal year.
Neurocrine Biosciences, Inc (NASDAQ:NBIX) discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.